Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study

Acta Cardiologica

Volumn 62, Issue 4, 2007, Pages 349-354

  Kumar, Adarsh ^a   Singh, Ram B ^b   Saxena, Manoj ^b   Niaz, Mohammad A ^b   Joshi, Shashank R ^c   Chattopadhyay, Pronobesh ^d   Mechirova, Viola ^e   Pella, Daniel ^e   Fedacko, Jan ^e  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b HALBERG HOSPITAL AND RESEARCH INSTITUTE   (India)

^c GRANT MEDICAL COLLEGE   (India)

^d IFTM   (India)

^e P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Antioxidants; Bio energetic; Free radical stress; Heart failure; Interleukin 6; Mitochondria; TNF alpha

Indexed keywords

ANTIEMETIC AGENT; CARNI Q GEL; CARNITINE; CARNITINE PLUS UBIQUINOL; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; VISUAL ANALOG SCALE; WALKING DIFFICULTY;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CARNITINE; CYTOKINES; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART RATE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; QUALITY OF LIFE; STROKE VOLUME; TUMOR NECROSIS FACTOR-ALPHA; UBIQUINONE; VITAMIN B COMPLEX; WALKING;

EID: 34548152791     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.62.4.2022278     Document Type: Article

References (24)

1. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure.: an overview. Heart 2004, 90: 464-70.
2. Mann DL. Inflammatory mediators and the failing heart: past, present and the foreseeable future. Circ Res 2002, 91: 988-98.
3. von Hachling S, Jankowska EA, Anker SD. Tumour necrosis factor alpha and the failing heart: pathophysiology and therapeutic implications. Basic Res Cardiol 2004, 99: 18-28.
4. Bolger AP, Anker SD. Tumor necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. Drugs 2000, 60: 1245-57.
5. Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol 2004, 94: 1306-10.
6. Singh RB, Pella D, Neki NS, Chandel JP, Rastogi S, Mori H, Otsuka K, Gupta P. Mechanisms of acute myocardial infarction study (MAMIS). Biomed Pharmacother 2004, 58 (Suppl 1): S111-5.
7. Singh RB, Pella D, Sharma JP, Rastogi S, Kartikey K, Goel VK, Sharma R, Neki NS, Kumar A, Otsuka K. Increased concentrations of lipoprotein(a), circadian rhythms and metabolic reactions, evoked by acute myocardial infarctions, associated with acute reactions, in relation to large breakfasts. Biomed Pharmacother 2004, 58 (Suppl 1): S116-22.
8. Sinatra ST, Sinatra J. L-carnitine and the heart. Keats Publishing, NTC Contemporary Publishing Group, Chicago, 1999, p. 7-35.
9. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356: 930-3.
10. Levine B, Kalman J, Mayer J. Elevated circulating levels of tumor necrosis factor alpha in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
11. Bhagvan HN, Chopra RK. Potential role of ubiquinone (coenzyme Q10) in pediatric cardiomyopathy. Clin Nutr 2005; 24: 331-8.
12. Singh RB, Niaz MA, Agarwal P, Beegum R, Rastogi SS, Sachan DS. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J 1996; 72: 45-50.
13. Esterbaur H, Cheeseman K. Determination of aldehyde peroxidation products malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990; 186: 407-21.
14. Niato C. Kawamura M, Yamamoto Y. Lipid peroxides as the initiating factor of atherosclerosis. NY Acad Sci 1993; 676: 27-45.
15. Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q formulations in human subjects. Int J Vit Nutr Res 1998; 68: 109-13.
16. Edlund PO. Determination of coenzyme Q, alpha-tocopherol and cholesterol in biological samples by coupled-column liquid chromatography with colorimetric and ultraviolet detection. J Chromatogr 1988; 425: 87-97.
17. Littarru GP, Ho L, Folkers K. Deficiency of coenzyme Q10 in human heart disease. II. Int J Vit Nutr Res 1972; 42: 291-5.
18. Folkers K, Littarru GP, Ho L, Runje TM, Havacoda S, Cooley D. Evidence for a deficiency of coenzyme Q10 in human heart disease. Int J Vit Res 1970; 40: 380-90.
19. Folkers K, Baker L, Richardson PC, Shizukuishi S, Takamura K, Drzewoski J, Lewandowski J, Ellis JM. Biomedical and clinical aspects of coenzyme Q, Vol. 2, Eds. Yamamura Y, Folkers K, Ito Y, Elsevier, Amsterdam, 1980; p. 449.
20. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Invest 1993, 71 (8 Suppl): S116-23.
21. Berman M, Erman A, Ben-Gal T, Dvir D, Georghiou GP, Stamler A, Vered Y, Vidne VA, Aravot D. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol 2004; 27: 295-9.
22. Hughes K, Lee BL, Feng X, Lee J, Ong CN. Coenzyme Q10 and differences in coronary heart disease risk in Asian Indians and Chinese. Free Rad Biol Med 2002; 32: 132-8.
23. Haeckel R, Raiser E, Oellerich M, Siliprandi N. Carnitine metabolism, function and implication. J Clin Chem Clin Metab 1990; 28: 291-5.
24. Wahlqvist ML, Wattanapenpaiboon N, Savige GS, Kannar D. Bioavailability of two different formulations of coenzyme Q10 in healthy subjects. Asia Pac J Clin Nutr 1998; 7: 37-40.